Gastro-oesophageal junction (GEJ) (GEJ)

The gastro-oesophageal junction (GEJ) is the anatomical region where the distal esophagus meets the proximal stomach. It serves a critical physiological role by acting as a functional sphincter to allow food passage into the stomach while preventing the reflux of acidic gastric contents back into the esophagus (StatPearls, 2023). While not a single molecular target itself, the GEJ is a significant clinical site for various pathologies, most notably gastro-oesophageal junction adenocarcinoma. This malignancy is a distinct clinical entity often requiring specific therapeutic approaches compared to gastric or esophageal cancers (PubMed, 2022). Therapeutic interventions at this site range from pharmacological acid suppression for reflux disease to complex systemic regimens for malignant conditions. Modern treatment for GEJ adenocarcinoma involves targeted therapies such as HER2-targeted agents like trastuzumab or checkpoint inhibitors like nivolumab (NCCN Guidelines, 2024). The management of GEJ-related diseases also involves surgical and endoscopic interventions to maintain luminal patency and prevent complications like Barrett's esophagus. Understanding the GEJ is essential for biotech analysts as it represents a high-growth area for oncology drug development and specialized medical devices.

Other names

Esophagogastric junctionEGJGastroesophageal junctionZ-lineCardia

Therapeutic strategies at this location involve acid suppression via proton pump inhibitors or H2-receptor antagonists for reflux, while oncological management targets specific molecular pathways such as HER2, VEGF, and PD-1/PD-L1 (NCCN Guidelines, 2024).